glp-1 prescriptions growth slowing 2024 Waistlines and GLP-1s—Expanding in Unison GLP1 agonists set to become

Other GLP-1 Agonists Exenatide: The EXSCEL trial (2017) showed a non-significant 9% MACE reduction (HR 0.91, 95% CI 0.831.00) in 14,752 T2DM patients, suggesting modest cardiovascular benefits [17]

If patients are asymptomatic from a GI standpoint and medications were held per guidance, their recommendation is to proceed with the procedure

Only fruits, leafy greens and water showed an overall increase in consumption

Kidney Impairment: While not always a disqualifier, patients with kidney disease must be monitored closely for dehydration, which can lead to acute kidney injury

doi: 10.1152/ajpcell.00153.2023 15

Official 2026 PA Timeline Data for Semaglutide Washington States Office of the Insurance Commissioner published official plan-year 2024 prior authorization response time data on January 1, 2026